Merck (MRK) Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy

The regimen pairs Merck's first-in-class oral HIF-2α inhibitor with Eisai-discovered lenvatinib, an orally available multi-receptor tyrosine kinase inhibitor. The recommendation moves the combination closer to a formal European Commission marketing authorization, which would expand Merck's oncology footprint in a competitive kidney cancer setting. Investors will watch for the European Commission's final decision and for uptake versus existing ccRCC regimens, with Merck's broader HIF-2α program and combination strategy in focus.